Pelthos Therapeutics Inc. (PTHS) — 8-K Filings

8-K Filings (21)

• Pelthos Therapeutics Files 8-K with Presentation Materials — Apr 14, 2026 Risk: low
  Pelthos Therapeutics Inc. filed an 8-K on April 14, 2026, disclosing information under Regulation FD. The filing includes a press release and company presentati
• Pelthos Therapeutics Inc. Files 8-K on Executive Changes — Dec 23, 2025 Risk: medium
  Pelthos Therapeutics Inc. filed an 8-K on December 23, 2025, reporting on the departure of directors or certain officers, the election of directors, the appoint
• Pelthos Therapeutics Files 8-K on Shareholder Votes — Dec 17, 2025 Risk: low
  Pelthos Therapeutics Inc. filed an 8-K on December 17, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as Ch
• Pelthos Therapeutics Files 8-K: Material Agreement, Debt, Equity Sales — Nov 7, 2025 Risk: medium
  Pelthos Therapeutics Inc. announced on November 7, 2025, that it entered into a material definitive agreement. The company also reported the creation of a direc
• Pelthos Therapeutics Files 8-K for Reg FD Disclosure — Oct 14, 2025 Risk: low
  Pelthos Therapeutics Inc. filed an 8-K on October 14, 2025, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or mate
• Pelthos Therapeutics Files 8-K for Reg FD Disclosure — Sep 3, 2025 Risk: low
  Pelthos Therapeutics Inc. filed an 8-K on September 3, 2025, reporting an event on September 2, 2025. The filing is primarily for Regulation FD Disclosure and i
• Pelthos Therapeutics Files 8-K on Financials — Aug 18, 2025 Risk: low
  Pelthos Therapeutics Inc. filed an 8-K on August 18, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation F
• Pelthos Therapeutics Reports Material Agreements & Equity Sales — Jul 2, 2025 Risk: medium
  Pelthos Therapeutics Inc. filed an 8-K on July 2, 2025, reporting several material events. These include entering into a definitive agreement, the completion of
• Channel Therapeutics Files 8-K — May 1, 2025 Risk: low
  Channel Therapeutics Corp. (formerly Chromocell Therapeutics Corp.) filed an 8-K on May 1, 2025, reporting on financial statements and exhibits. The company, in
• Channel Therapeutics Corp. Files 8-K with Material Agreements & Updates — Apr 17, 2025 Risk: medium
  On April 17, 2025, Channel Therapeutics Corp. (formerly Chromocell Therapeutics Corp.) entered into a material definitive agreement. The company also reported o
• Channel Therapeutics Corp. Enters Material Definitive Agreement — Mar 3, 2025 Risk: medium
  On February 25, 2025, Channel Therapeutics Corp. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly kno
• Channel Therapeutics Corp. Files 8-K — Nov 21, 2024 Risk: low
  On November 21, 2024, Channel Therapeutics Corp. (formerly Chromocell Therapeutics Corp.) filed an 8-K report. The filing indicates the company's principal exec
• Channel Therapeutics Corp. Files 8-K with Major Corporate Updates — Nov 18, 2024 Risk: medium
  Channel Therapeutics Corp. announced on November 18, 2024, a material definitive agreement, the creation of a direct financial obligation, and modifications to
• Chromocell Therapeutics Corp Files 8-K — Oct 24, 2024 Risk: low
  On October 22, 2024, Chromocell Therapeutics Corporation filed an 8-K report detailing a submission of matters to a vote of security holders, other events, and
• Chromocell Therapeutics Files 8-K — Aug 7, 2024 Risk: low
  Chromocell Therapeutics Corporation filed an 8-K on August 7, 2024, reporting an event that occurred on August 5, 2024. The filing is categorized under 'Other E
• Chromocell Therapeutics Reports Material Agreement and Financial Updates — Jul 29, 2024 Risk: medium
  Chromocell Therapeutics Corporation entered into a material definitive agreement on July 24, 2024. The company also incurred a direct financial obligation or an
• Chromocell Therapeutics Files 8-K — Apr 9, 2024 Risk: low
  Chromocell Therapeutics Corporation filed an 8-K on April 9, 2024, to report other events and financial statements. The filing details the company's principal e
• Chromocell Therapeutics Files 8-K — Mar 21, 2024 Risk: low
  Chromocell Therapeutics Corporation filed an 8-K on March 21, 2024, reporting on its current activities. The filing includes information regarding financial sta
• Chromocell Therapeutics Moves HQ, Files Officer/Director Changes — Mar 18, 2024 Risk: medium
  Chromocell Therapeutics Corp. announced on March 13, 2024, a change in its principal executive office to 4400 Route 9 South, Suite 1000, Freehold, NJ 07728. Thi
• Chromocell Therapeutics Files 8-K — Mar 13, 2024 Risk: low
  Chromocell Therapeutics Corp. filed an 8-K on March 13, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not co
• Chromocell Therapeutics Amends Bylaws, Sells Equity — Feb 22, 2024 Risk: medium
  Chromocell Therapeutics Corp. entered into a Material Definitive Agreement on February 15, 2024, involving an unregistered sale of equity securities. This event

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX